Suppr超能文献

在已建立的爆炸相关创伤损伤模型中,靶向刺激视黄酸受体γ可减轻异位骨化的形成。

Targeted stimulation of retinoic acid receptor-γ mitigates the formation of heterotopic ossification in an established blast-related traumatic injury model.

作者信息

Pavey Gabriel J, Qureshi Ammar T, Tomasino Allison M, Honnold Cary L, Bishop Danett K, Agarwal Shailesh, Loder Shawn, Levi Benjamin, Pacifici Maurizio, Iwamoto Masahiro, Potter Benjamin K, Davis Thomas A, Forsberg Jonathan A

机构信息

Regenerative Medicine Department, Naval Medical Research Center, Silver Spring, MD, United States; USU-Walter Reed Surgery, Walter Reed National Military Medical Center, Bethesda, MD, United States.

Regenerative Medicine Department, Naval Medical Research Center, Silver Spring, MD, United States.

出版信息

Bone. 2016 Sep;90:159-67. doi: 10.1016/j.bone.2016.06.014. Epub 2016 Jun 28.

Abstract

Heterotopic ossification (HO) involves formation of endochondral bone at non-skeletal sites, is prevalent in severely wounded service members, and causes significant complications and delayed rehabilitation. As common prophylactic treatments such as anti-inflammatory drugs and irradiation cannot be used after multi-system combat trauma, there is an urgent need for new remedies. Previously, we showed that the retinoic acid receptor γ agonist Palovarotene inhibited subcutaneous and intramuscular HO in mice, but those models do not mimic complex combat injury. Thus, we tested Palovarotene in our validated rat trauma-induced HO model that involves blast-related limb injury, femoral fracture, quadriceps crush injury, amputation and infection with methicillin-resistant Staphylococcus aureus from combat wound infections. Palovarotene was given orally for 14days at 1mg/kg/day starting on post-operative day (POD) 1 or POD-5, and HO amount, wound dehiscence and related processes were monitored for up to 84days post injury. Compared to vehicle-control animals, Palovarotene significantly decreased HO by 50 to 60% regardless of when the treatment started and if infection was present. Histological analyses showed that Palovarotene reduced ectopic chondrogenesis, osteogenesis and angiogenesis forming at the injury site over time, while fibrotic tissue was often present in place of ectopic bone. Custom gene array data verified that while expression of key chondrogenic and osteogenic genes was decreased within soft tissues of residual limb in Palovarotene-treated rats, expression of cartilage catabolic genes was increased, including matrix metalloproteinase-9. Importantly, Palovarotene seemed to exert moderate inhibitory effects on wound healing, raising potential safety concerns related to dosing and timing. Our data show for the first time that Palovarotene significantly inhibits HO triggered by blast injury and associated complications, strongly indicating that it may prevent HO in patients at high risk such as those sustaining combat injuries and other forms of blast trauma.

摘要

异位骨化(HO)是指在非骨骼部位形成软骨内骨,在重伤员中很常见,并会导致严重并发症和康复延迟。由于多系统战斗创伤后不能使用如抗炎药物和放射治疗等常规预防性治疗方法,因此迫切需要新的治疗方法。此前,我们发现视黄酸受体γ激动剂帕罗西汀可抑制小鼠皮下和肌肉内的异位骨化,但这些模型无法模拟复杂的战斗损伤。因此,我们在经过验证的大鼠创伤诱导异位骨化模型中测试了帕罗西汀,该模型涉及爆炸相关的肢体损伤、股骨骨折、股四头肌挤压伤、截肢以及因战斗伤口感染耐甲氧西林金黄色葡萄球菌。从术后第1天(POD)或POD - 5开始,帕罗西汀以1mg/kg/天的剂量口服给药14天,并在受伤后长达84天内监测异位骨化量、伤口裂开及相关过程。与赋形剂对照动物相比,无论治疗何时开始以及是否存在感染,帕罗西汀均能使异位骨化显著减少50%至60%。组织学分析表明,随着时间的推移,帕罗西汀减少了损伤部位异位软骨形成、骨形成和血管生成,而异位骨常被纤维组织取代。定制基因阵列数据证实,在帕罗西汀治疗的大鼠残肢软组织中,关键软骨生成和成骨基因的表达降低,而软骨分解代谢基因的表达增加,包括基质金属蛋白酶 - 9。重要的是,帕罗西汀似乎对伤口愈合有中度抑制作用,这引发了与给药剂量和时间相关的潜在安全问题。我们的数据首次表明,帕罗西汀能显著抑制爆炸伤引发的异位骨化及相关并发症,有力地表明它可能预防高危患者如遭受战斗损伤和其他形式爆炸创伤患者的异位骨化。

相似文献

5
BMP Ligand Trap ALK3-Fc Attenuates Osteogenesis and Heterotopic Ossification in Blast-Related Lower Extremity Trauma.
Stem Cells Dev. 2021 Jan 15;30(2):91-105. doi: 10.1089/scd.2020.0162. Epub 2020 Dec 24.
6
Early Characterization of Blast-related Heterotopic Ossification in a Rat Model.
Clin Orthop Relat Res. 2015 Sep;473(9):2831-9. doi: 10.1007/s11999-015-4240-y.
7
Bioburden Increases Heterotopic Ossification Formation in an Established Rat Model.
Clin Orthop Relat Res. 2015 Sep;473(9):2840-7. doi: 10.1007/s11999-015-4272-3.

引用本文的文献

3
Pay Attention to the Osteochondromas in Fibrodysplasia Ossificans Progressiva.
Orthop Surg. 2024 Mar;16(3):781-787. doi: 10.1111/os.13956. Epub 2024 Jan 7.
5
International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023.
Pharmacol Rev. 2023 Nov;75(6):1233-1318. doi: 10.1124/pharmrev.121.000436. Epub 2023 Aug 16.
6
Pathophysiology and Emerging Molecular Therapeutic Targets in Heterotopic Ossification.
Int J Mol Sci. 2022 Jun 23;23(13):6983. doi: 10.3390/ijms23136983.
7
A Network Pharmacology Study: Reveal the Mechanisms of Palovarotene Against Heterotopic Ossification.
Front Med (Lausanne). 2022 May 13;9:897392. doi: 10.3389/fmed.2022.897392. eCollection 2022.
10
Palovarotene: First Approval.
Drugs. 2022 Apr;82(6):711-716. doi: 10.1007/s40265-022-01709-z.

本文引用的文献

2
What Risk Factors Predict Recurrence of Heterotopic Ossification After Excision in Combat-related Amputations?
Clin Orthop Relat Res. 2015 Sep;473(9):2814-24. doi: 10.1007/s11999-015-4266-1.
3
Bioburden Increases Heterotopic Ossification Formation in an Established Rat Model.
Clin Orthop Relat Res. 2015 Sep;473(9):2840-7. doi: 10.1007/s11999-015-4272-3.
5
Early Characterization of Blast-related Heterotopic Ossification in a Rat Model.
Clin Orthop Relat Res. 2015 Sep;473(9):2831-9. doi: 10.1007/s11999-015-4240-y.
6
Treatment of heterotopic ossification through remote ATP hydrolysis.
Sci Transl Med. 2014 Sep 24;6(255):255ra132. doi: 10.1126/scitranslmed.3008810.
7
Do inflammatory markers portend heterotopic ossification and wound failure in combat wounds?
Clin Orthop Relat Res. 2014 Sep;472(9):2845-54. doi: 10.1007/s11999-014-3694-7. Epub 2014 May 31.
8
Reoperation after combat-related major lower extremity amputations.
J Orthop Trauma. 2014 Apr;28(4):232-7. doi: 10.1097/BOT.0b013e3182a53130.
9
Characterization of heterotopic ossification in burn patients.
J Burn Care Res. 2014 May-Jun;35(3):251-6. doi: 10.1097/BCR.0b013e3182957768.
10
Ectopic bone formation in severely combat-injured orthopedic patients -- a hematopoietic niche.
Bone. 2013 Sep;56(1):119-26. doi: 10.1016/j.bone.2013.05.016. Epub 2013 May 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验